An Overview of Diabetic Nephropathy

被引：2

作者：

Atasoy, Alp ^{[1
]}

Atay, Ali ^{[1
]}

Ahbab, Suleyman ^{[1
]}

Hanedar, Maksude ^{[1
]}

Yenigun, Mustafa ^{[1
]}

机构：

[1] Haseki Egitim & Arastirma Hastanesi, Ic Hastaliklari Klin, Istanbul, Turkey

来源：

HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI | 2015年 / 53卷 / 01期

关键词：

Diabetes mellitus; nephropathy;

D O I：

10.4274/haseki.1913

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diabetic nephropathy is a significant cause of morbidity and mortality associated with a high risk of cardiovascular complications. The primary goal should be treatment and control of risk factors. Structural changes due to diabetic nephropathy may affect all the renal compartments. Atherosclerotic renal artery stenosis and arteriolosclerosis constitute an important part of systemic vascular lesions in diabetics. Close monitoring of blood pressure and glycemic control is important in the prevention of microvascular complications. In this review, we aimed to give an outline of diabetic nephropathy which is an increasing public health problem and to draw attention to this condition.

引用

页码：16 / 19

页数：4

共 17 条

[1] Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists
Azizi, M
Ménard, J
[J]. CIRCULATION, 2004, 109 (21) : 2492 - 2499
[2] Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy
Bakris, GL
Copley, JB
Vicknair, N
Sadler, R
Leurgans, S
[J]. KIDNEY INTERNATIONAL, 1996, 50 (05) : 1641 - 1650
[3] Nephropathy Following Type 2 Diabetes Mellitus in Tunisian Population
Bouaziz, A.
Zidi, I.
Zidi, N.
Mnif, W.
Zinelabidine, H. T.
[J]. WEST INDIAN MEDICAL JOURNAL, 2012, 61 (09) : 881 - 889
[4] THE EFFECT OF ALDOSE REDUCTASE INHIBITORS ON GLOMERULAR PROSTAGLANDIN PRODUCTION AND URINARY ALBUMIN EXCRETION IN EXPERIMENTAL DIABETES-MELLITUS
CHANG, WP
DIMITRIADIS, E
ALLEN, T
DUNLOP, ME
COOPER, M
LARKINS, RG
[J]. DIABETOLOGIA, 1991, 34 (04) : 225 - 231
[5] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Chobanian, AV
Bakris, GL
Black, HR
Cushman, WC
Green, LA
Izzo, JL
Jones, DW
Materson, BJ
Oparil, S
Wright, JT
Roccella, EJ
[J]. HYPERTENSION, 2003, 42 (06) : 1206 - 1252
[6] Treatment of the patient with diabetes mellitus and risk of nephropathy - What do we know, and what do we need to learn?
Hollenberg, NK
[J]. ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (02) : 125 - 130
[7] Jindal R M, 2012, Indian J Nephrol, V22, P484, DOI 10.4103/0971-4065.106049
[8] Diabetes and renal disease: who does what?
Jones, Ruth K.
Hampton, David
O'Sullivan, Daniel J.
Phillips, Aled O.
[J]. CLINICAL MEDICINE, 2013, 13 (05) : 460 - 464
[9] The emerging role of VEGF in diabetic kidney disease
Khamaisi, M
Schrijvers, BF
De Vriese, AS
Raz, I
Flyvbjerg, A
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (08) : 1427 - 1430
[10] Lewis EJ, 2004, J AM SOC NEPHROL, V15, P1358

← 1 2 →